Treatment Adherence of Anti-TNF Drugs in the Patients with Inflammatory Bowel Disease: A Scale Development Study

被引:0
|
作者
Basak, Nur [1 ]
Uran, Berna Nilgun Ozgursoy [2 ]
Yuksel, Elif Saritas [3 ]
机构
[1] Izmir Katip Celebi Univ, Inst Hlth Sci, Internal Med Nursing Dept, Izmir, Turkey
[2] Izmir Katip Celebi Univ, Fac Hlth Sci, Izmir, Turkey
[3] Izmir Katip Celebi Univ, Med Sch, Izmir, Turkey
来源
TURKISH JOURNAL OF GASTROENTEROLOGY | 2022年 / 33卷 / 04期
关键词
Anti-TNF alpha; IBD; reliability; scale development; treatment compliance; validity; MEDICATION ADHERENCE; THERAPY; NONADHERENCE; RISK;
D O I
10.5152/tjg.2022.211170
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: This work studies the validity and reliability of the Anti-TNF Alpha Treatment Adherence Scale, which has newly been developed to measure the compliance of inflammatory bowel disease patients using the anti-TNF alpha agents that are widely used in gastroenterology and rheumatology clinics. Methods: The study group consisted of 165 irritable bowel disease patients aged 18 years and above who were using anti-TNF alpha drugs. After creating a question pool with 40 items, the pilot study was applied with 70 patients. SPSS 25.0 and AMOS programs were used. item-total correlation coefficients, Cronbach's alpha and test-retest analysis, missing data, extreme value, normality, 27% sub-upper item discrimination analysis, and exploratory and confirmatory factor analyses were used. Results: The factor structure of the scale was examined with exploratory and confirmatory factor analyses and the contribution of these components to the total variance was measured as 74.21%. The Anti-TNF Alpha Treatment Adherence Scale was found in relation to the scale structure consisting of 12 items and 4 sub-dimensions. According to the first level multifactorial analysis results, the goodness of fit identities of the scale were found at an acceptable level, with the following values: RMSEA 0.067; GFI 0.92; AGFI 0.87; CFI 0.95; and chi(2) 79.876 (P = .000). Conclusion: It was determined that the Anti-TNF Alpha Treatment Adherence Scale represents the area to be measured, measures the researched structure, has a high internal consistency between items, is interrelated, and is consistent over time. As a result of all measurements, it was determined that it is a valid and reliable scale.
引用
收藏
页码:336 / +
页数:12
相关论文
共 50 条
  • [31] Impact of Race on ANTI-TNF Immunogenicity in Patients with Inflammatory Bowel Disease
    Nawaz, Ahmad
    Chaar, Abdelkader
    Li, Darrick K.
    Gaidos, Jill K.
    Proctor, Deborah
    Al-Bawardy, Badr
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2022, 117 (10): : S623 - S624
  • [32] ANTI-TNF THERAPY INDUCED ARTHRITIS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
    Reilly, Elizabeth
    Edwards, Cathryn
    Mackay, Kirsten
    RHEUMATOLOGY, 2015, 54 : 94 - 94
  • [33] Microreinduction of injectable anti-TNF therapy in Patients with Inflammatory Bowel Disease
    Ligler, Robin
    Horst, Sara
    Duley, Caroline
    Wagnon, Julianne
    Beaulieu, Dawn
    Schwartz, David
    INFLAMMATORY BOWEL DISEASES, 2011, 17 : S41 - S42
  • [34] Ustekinumab and Anti-TNF Combination Therapy in Patients with Inflammatory Bowel Disease
    Yzet, Clara
    Dupas, Jean-Louis
    Fumery, Mathurin
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2016, 111 (05): : 748 - 749
  • [35] Lipid Profile in Inflammatory Bowel Disease Patients on Anti-TNFα Therapy
    Miranda-Bautista, Jose
    de Gracia, Celia
    Lopez-Ibanez, Maria
    Barrientos, Maria
    Marin-Jimenez, Ignacio
    Diaz-Redondo, Alicia
    Menchen, Luis
    GASTROENTEROLOGY, 2014, 146 (05) : S577 - S577
  • [36] Lipid Profile in Inflammatory Bowel Disease Patients on Anti-TNFα Therapy
    José Miranda-Bautista
    Celia de Gracia-Fernández
    María López-Ibáñez
    María Barrientos
    Alejandra Gallo-Moltó
    Marina González-Arias
    Casilda González-Gil
    Alicia Díaz-Redondo
    Ignacio Marín-Jiménez
    Luis Menchén
    Digestive Diseases and Sciences, 2015, 60 : 2130 - 2135
  • [37] Involvement of HLADQA1*05 in Patients with Inflammatory Bowel Disease Treated with Anti-TNF Drugs
    Pau, Anna
    Galliano, Ilaria
    Barnini, Elisa
    Dini, Maddalena
    Pizzol, Antonio
    Ponte, Alice
    Gambarino, Stefano
    Calvo, Pier Luigi
    Bergallo, Massimiliano
    MEDICINA-LITHUANIA, 2025, 61 (01):
  • [38] Inflammatory bowel disease: anti-TNF strategies and beyond
    Hoffmann, JC
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2004, 129 : S76 - S78
  • [39] Optimizing anti-TNF treatments in inflammatory bowel disease
    Ben-Horin, Shomron
    Kopylov, Uri
    Chowers, Yehuda
    AUTOIMMUNITY REVIEWS, 2014, 13 (01) : 24 - 30
  • [40] Loss of response to anti-TNFα agents depends on treatment duration in patients with inflammatory bowel disease
    Schultheiss, Johannes P. D.
    Mahmoud, Remi
    Louwers, Jonas M.
    van der Kaaij, Michiel T.
    van Hellemondt, Boris P.
    van Boeckel, Petra G.
    Mahmmod, Nofel
    Jharap, Bindia
    Fidder, Herma H.
    Oldenburg, Bas
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2021, 54 (10) : 1298 - 1308